What you should know:
1. The companies will use Finch’s Human-First Discovery platform to develop the treatment. The platform develops treatments that contain microbiota from human donors as well as bacterial strains that contributed to favorable clinical outcomes in studies.
2. If Finch succeeds, Takeda will receive exclusive commercialization rights.
3. Neither company disclosed the financial terms of the deal.
More articles on surgery centers:
CMS to pay for total knees in ASCs, boost ASC payment rate 2.6% in 2020: 4 details
With $60B+ deals this year, what’s in store for private equity in the future?
Texas health system building ASC — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
